Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...

Eli Lilly fell short of Wall Street sales estimates for its weight-loss and diabetes drugs on Wednesday, hit by a decrease in ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high ...

Eli Lilly (LLY) and Company announced detailed results from ... Tirzepatide demonstrated sustained average weight loss of 22.9% through the three-year treatment period for the efficacy estimand. These ...

Conditions are getting a bit more challenging for the drugmaker.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Earlier in October, Eli Lilly missed on both the top and bottom lines in its Q3 financial results, but its sales grew 20%, ...